Loading company
Savara Inc
SVRA · Nasdaq · ·
Next earnings: November 11, 2026
$5.10+0.4%Sep 29 close
- 1M
- -3.0%
- 6M
- +1.0%
- 1Y
- +42.9%
- 5Y
- +295.3%
SVRA · Nasdaq · ·
Next earnings: November 11, 2026
$5.10+0.4%Sep 29 close
Savara Inc is scheduled to report next on November 11, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending September 30, 2021, against the same quarter a year earlier.
| Measure | 3 months toSep 30, 2021 | 3 months toMar 31, 2020 | Change |
|---|---|---|---|
| Total Revenue | $0.00 | $0.00 | — |
| Profit | -$40.2M | -$30.4M | -32.32% |
| Profit per share | -$0.16 | -$0.14 | -14.29% |
| Free Cash Flow | -$30M | -$26.3M | -14.05% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Savara is an orphan lung disease company with a pipeline comprised of three investigational compounds, all of which use an inhaled delivery route. Our lead program, Molgradex, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP) and in Phase 2a development for nontuberculous mycobacterial (NTM) lung infection in both non-cystic fibrosis and cystic fibrosis-affected individuals. Apulmiq is an inhaled ciprofloxacin in Phase 3 development for non-cystic fibrosis bronchiectasis (NCFB). AeroVanc is an inhaled vancomycin in Phase 3 development for persistent methicillin-resistant Staphylococcus aureus (MRSA) lung infection in people living with cystic fibrosis. Savaras strategy involves broadening its pipeline through indication expansion, strategic development partnerships and product acquisitions, with the goal of becoming a leading company in its field. Our management team has significant experience in orphan drug development and pulmonary medicine, identifying unmet needs, developing and acquiring 2 new product candidates, and effectively advancing them to approval and commercialization. More information can be found at www.savarapharma.com . (Twitter: @SavaraPharma , LinkedIn: www.linkedin.com/company/savara-pharmaceuticals/ ).
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Savara Inc’s Item 2.02 8-K filed August 6, 2020; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Savara Inc has no earnings call transcript available.